 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...5051525354555657585960...208209» |
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: Pyrotinib induces cell death in HER2-positive breast cancer via triggering HSP90-dependent HER2 degradation and ROS/HSF-1-dependent oxidative DNA damage. (Pubmed Central) - Dec 14, 2024
Furthermore, the in vivo results demonstrated a pronounced anticancer effect of pyrotinib in the SKBR3 xenograft mouse model, concomitant with a reduction in HER2 expression. In summary, our findings provide novel insights into the mechanism of pyrotinib in the treatment of HER2+ BC.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Neoadjuvant Camrelizumab for Triple-Negative Breast Cancer. (Pubmed Central) - Dec 13, 2024
In summary, our findings provide novel insights into the mechanism of pyrotinib in the treatment of HER2+ BC. No abstract available
- | Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Journal, HEOR, Real-world evidence, Real-world: Real-world evidence of avatrombopag for the treatment of immune thrombocytopenia intolerant or ineffective to eltrombopag/hetrombopag. (Pubmed Central) - Dec 12, 2024
Patients benefited from TPO-RAs switches, particularly those undergoing multiple switches. However, many patients struggled with the long-term financial burden of AVA.
- || Pegylated rhG-CSF (mecapegfilgrastim) / Jiangsu Hengrui Pharma
P2 data, Journal, Metastases: Mecapegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia in locally advanced nasopharyngeal carcinoma: A prospective phase II clinical study. (Pubmed Central) - Dec 12, 2024
However, many patients struggled with the long-term financial burden of AVA. Mecapegfilgrastim effectively reduced the incidence of chemotherapy-induced neutropenia and FN in patients with locally advanced nasopharyngeal carcinoma.
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
New P2 trial: JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC (clinicaltrials.gov) - Dec 12, 2024
P2, N=40, Not yet recruiting, Sponsor: Fudan University
- ||| AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
Trial completion, Trial completion date, Trial primary completion date: Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis (clinicaltrials.gov) - Dec 12, 2024
P2, N=112, Completed, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Mecapegfilgrastim effectively reduced the incidence of chemotherapy-induced neutropenia and FN in patients with locally advanced nasopharyngeal carcinoma. Recruiting --> Completed | Trial completion date: Jan 2023 --> Jun 2024 | Trial primary completion date: Jan 2023 --> Jun 2024
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
New P2 trial: Resilire: Reverse HER2-negative Immune Resistant Breast Cancer (clinicaltrials.gov) - Dec 12, 2024
P2, N=10, Recruiting, Sponsor: Fudan University
- |||||| garetatug rezetecan (SHR-A1904) / EMD Serono
Enrollment open: SHR-A1904-302: SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Dec 12, 2024
P3, N=524, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Recruiting --> Completed | Trial completion date: Jan 2023 --> Jun 2024 | Trial primary completion date: Jan 2023 --> Jun 2024 Not yet recruiting --> Recruiting
- | M9466 / EMD Serono, AiRuiKa (camrelizumab) / Elevar Therapeutics, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Enrollment open, Trial initiation date, IO biomarker: Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib (clinicaltrials.gov) - Dec 11, 2024
P2, N=130, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jul 2024 --> Sep 2024
- || AiRuiKa (camrelizumab) / HLB Bio Group
Review, Journal, Checkpoint inhibition: Refractory hypokalemia and metabolic acidosis induced by undifferentiated connective tissue disease secondary to immune checkpoint inhibitors: a case report and literature review. (Pubmed Central) - Dec 11, 2024
Refractory hypokalemia and RTA were attributed to undifferentiated connective tissue disease (UCTD), a rheumatic condition considered as an adverse event of camrelizumab. This case underscores the necessity of monitoring serum potassium levels during ICI therapy and the consideration of RTA and autoimmune diseases in cases of hypokalemia to prevent serious adverse consequences.
- | Ibrance (palbociclib) / Pfizer, AiRuiKa (camrelizumab) / Elevar Therapeutics
Trial initiation date: Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas (clinicaltrials.gov) - Dec 11, 2024
P1, N=6, Recruiting, Sponsor: West China Hospital
This case underscores the necessity of monitoring serum potassium levels during ICI therapy and the consideration of RTA and autoimmune diseases in cases of hypokalemia to prevent serious adverse consequences. Initiation date: Dec 2024 --> Aug 2024
- || HRS-5965 / Jiangsu Hengrui Pharma
Enrollment open: HRS-5965-103: Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment (clinicaltrials.gov) - Dec 11, 2024
P1, N=28, Recruiting, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
Initiation date: Dec 2024 --> Aug 2024 Not yet recruiting --> Recruiting
- ||| HRS-7535 / Kailera Therapeutics
New P1 trial: Study on Drug Interaction of Metformin Tablets and HRS-7535 Tablets in Healthy Human (clinicaltrials.gov) - Dec 11, 2024
P1, N=54, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
- | Biomarker, Enrollment open: NUMER: Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. (clinicaltrials.gov) - Dec 10, 2024
P2, N=120, Recruiting, Sponsor: Sun Yat-sen University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | rivocibart (SHR-1918) / Jiangsu Hengrui Pharma
Enrollment closed: Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia (clinicaltrials.gov) - Dec 10, 2024
P2, N=44, Active, not recruiting, Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- ||| SHR-A2102 / Jiangsu Hengrui Pharma
Enrollment open, Metastases: SHR-A2102-208: A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy (clinicaltrials.gov) - Dec 9, 2024
P2, N=100, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / Elevar Therapeutics
Enrollment change, Trial withdrawal: APPEAL: APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC (clinicaltrials.gov) - Dec 9, 2024
P2, N=0, Withdrawn, Sponsor: Sun Yat-sen University
Not yet recruiting --> Recruiting N=128 --> 0 | Recruiting --> Withdrawn
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open, Trial initiation date: Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis (clinicaltrials.gov) - Dec 9, 2024
P2, N=30, Recruiting, Sponsor: Beijing 302 Hospital
N=128 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting | Initiation date: May 2024 --> Oct 2024
- |||| rivocibart (SHR-1918) / Jiangsu Hengrui Pharma
New P3 trial: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia (clinicaltrials.gov) - Dec 9, 2024
P3, N=45, Not yet recruiting, Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
- ||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
New P1 trial: Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects (clinicaltrials.gov) - Dec 8, 2024
P1, N=57, Not yet recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
- Pegylated rhG-CSF (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Mecapegfilgrastim for Preventing Chemotherapy-Induced Neutropenia in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Open-Label, Randomized Controlled Trial () - Dec 7, 2024 - Abstract #ASH2024ASH_8548;
P2
The incidence of serious TEAEs was 7.1% in both groups, and one patient in the study group died due to interstitial lung disease, all of which were deemed unrelated to mecapegfilgrastim.Conclusions : Mecapegfilgrastim demonstrated a good safety profile and a nonsignificant trend towards reduced incidence of grade 3/4 chemotherapy-induced neutropenia in DLBCL patients, underscoring its potential as a prophylactic option. Further study is warranted to validate these findings.
- AiRuiKa (camrelizumab) / HLB Bio Group, Oncaspar liquid (pegaspargase) / Servier, Itari (linperlisib) / Shanghai YingLi Pharma
A Phase Ib/II Clinical Trial of Linperlisib Combined with Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-Cell Lymphoma: Analysis of the Phase Ib Part () - Dec 7, 2024 - Abstract #ASH2024ASH_8466;
P1/2
Now, the phase II study is ongoing.Conclusions : Linperlisib combined with camrelizumab and pegaspargase was well tolerated and efficacious in patients with advanced or relapsed/refractory NK/T-cell Lymphoma. The efficacy and safety profiles will be verified in the ongoing phase II study.
- Itari (linperlisib) / Shanghai YingLi Pharma
Linperlisib in Combination with CHOP for Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from the Phase 1b/2 Linch Study () - Dec 7, 2024 - Abstract #ASH2024ASH_8460;
P1/2, P2
The efficacy and safety profiles will be verified in the ongoing phase II study. In phase 1b, 6 patients received 6 cycles of L-CHOP regimen : linperlisib 80 mg orally once daily on days 1 to 21, cyclophosphamide 750 mg/m
- Itari (linperlisib) / Shanghai YingLi Pharma
Linperlisib Combined with CHOP Regimen Followed By Autologous Hematopoietic Stem Cell Transplantation and Linperlisib Monotherapy Maintenance for Newly Diagnosed Nodal T-Follicular Helper Cell Lymphoma Patients: A Phase II Trial () - Dec 7, 2024 - Abstract #ASH2024ASH_8443;
P2
Treatment discontinuations due to TRAEs occurred in 13.33% (2/15) of patients.Conclusion : Linperlisib combined with CHOP shows promising efficacy and manageable safety in newly diagnosed nTFHL patients. This study is ongoing, and further long-term data are anticipated.
- Venclexta (venetoclax) / Roche, AbbVie, Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
Chemotherapy-Free Treatment with Venetoclax, Azacitidine and Flumatinib Induces an Early and Deep Molecular Response in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:What Is the Underlying Mechanism? () - Dec 7, 2024 - Abstract #ASH2024ASH_7995;
Azacitidine and flumatinib enhance venetoclax-induced apoptosis in Ph+ALL cells by upregulating pro-apoptotic proteins NOXA and BIM, and downregulating the anti-apoptotic protein MCL-1. Our study provided a theoretical foundation for the clinical efficacy of VAF regimen.
- Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
Flumatinib with Low-Intensity Chemotherapy in Elderly Patients with Newly Diagnosed BCR::ABL1-Positive Acute Lymphoblastic Leukemia () - Dec 7, 2024 - Abstract #ASH2024ASH_7963;
Central nervous system (CNS) prophylaxis is regularly performed by intrathecal injection of methotrexate, cytarabine, and dexamethasone after the induction course...The clinical outcomes observed for flumatnib were comparable to those reported for the classical second-generation TKI dasatinib. These findings will be further validated through long-term follow-up with an expanded sample size.
- cyclosporine / Generic mfg.
Efficacy and Safety of Different TPO-RAs Combined with Cyclosporine in the Treatment of NSAA () - Dec 7, 2024 - Abstract #ASH2024ASH_7767;
Avatrombopag has advantages in patients with underlying liver diseases. Bone marrow residual hematopoiesis and adequate TPO-RAs dosage are independent factors for achieving good efficacy at 6 months.
- cyclophosphamide / Generic mfg.
Cyclophosphamide Combined with Standard Immunosuppressive Therapy Improves Early Response Outcomes in Severe Aplastic Anemia () - Dec 7, 2024 - Abstract #ASH2024ASH_7761;
The infection rate within 3 months was 58.3% (21/36). The mortality rate within 3 months was 0%.Conclusion : Cyclophosphamide in combination with standard immunosuppressive therapy as first-line treatment shows good safety and efficacy, with two-thirds of patients achieving a response and becoming transfusion-independent within 3 months.
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Recombinant Human Thrombopoietin Combined with Thrombopoietin Receptor Agonists Can Facilitate the Recovery of Platelet after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma () - Dec 7, 2024 - Abstract #ASH2024ASH_7527;
There were no statistical differences in the incidence of adverse events, total expense and hospital stay between two groups (P > 0.05).ConclusionsOur data shows that the treatment protocol of TPO-RA (hetrombopag) combined with rh-TPO may boost a faster platelet growth rate. Importantly, no additional adverse effects occurred when the addition of TPO-RA.
- Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated By Prolonged Thrombocytopenia: A Comprehensive Review () - Dec 7, 2024 - Abstract #ASH2024ASH_7522;
shows a simplified flowchart for the suggested use of second-generation TpoR agonists in post-HCT thrombocytopenia. Nevertheless, the overall efficacy and safety of TpoR agonist agents post-HCT necessitate further exploration through larger, well-structured clinical trials to optimize their use and ensure their place in standard clinical practice
- Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis, Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Combination of All-Trans Retinoic Acid Resumes the Sustained Response of TPO-RA in ITP () - Dec 7, 2024 - Abstract #ASH2024ASH_7512;
The rate of hair loss was 13.33% (2/15). The rate of rash was 6.67% (1/15).Our data shows that short-term treatment of ATRA in ITP during platelet fluctuation by TPO-RA may be effective and safe.
- Mulpleta (lusutrombopag) / Shionogi
A Prospective Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lusutrombopag in Chinese Adults with Persistent or Chronic Primary Immune Thrombocytopenia () - Dec 7, 2024 - Abstract #ASH2024ASH_7506;
P2
The rate of rash was 6.67% (1/15).Our data shows that short-term treatment of ATRA in ITP during platelet fluctuation by TPO-RA may be effective and safe. TPO-RAs (romiplostim, eltrombopag, hetrombopag, and avatrombopag) has been approved for treating ITP in Chinese...Prior to enrollment, 50% had been receiving stable steroids (same milligram amount
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Real-World Effectiveness of Hetrombopag for Cancer Therapy-Induced Thrombocytopenia in Cancer Patients () - Dec 7, 2024 - Abstract #ASH2024ASH_7494;
The 14-day response rates were 91.3% (21/23), 84.1% (37/44), 64.0% (16/25), and 56.3% (9/16), respectively.The 28-day response rates were 95.7% (22/23), 90.9% (40/44), 76.0% (19/25), and 56.3% (9/16), respectively.Conclusion : The results of this study suggest that under real world conditions, oral hetrombopag monotherapy and combinations with rh-IL-11 or rh-TPO are effective treatment options for CTIT, demonstrating high response rates and a short time to recovery in a mixed patient population. These findings are hypothesis-generating and need confirmation in randomized trials in the future.
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Efficacy and Safety of Hetrombopag in the Treatment of Chemotherapy-Induced Thrombocytopenia in Pediatric Acute Leukemia () - Dec 7, 2024 - Abstract #ASH2024ASH_7493;
Hetrombopag can significantly improve platelet counts within a short period, reduce hospital stay duration, minimize bleeding risks, and decrease the need for emergency treatments. Further validation with large sample size and prospective clinical studies are needed.
- ||| M9466 / EMD Serono
New P1 trial: Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) (clinicaltrials.gov) - Dec 5, 2024
P1, N=54, Not yet recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P1/2 trial: Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain Metastasis (clinicaltrials.gov) - Dec 5, 2024
P1/2, N=74, Not yet recruiting, Sponsor: Fudan University
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New trial: Pyrotinib in HER2-positive Early Breast Cancer (clinicaltrials.gov) - Dec 5, 2024
P=N/A, N=156, Not yet recruiting, Sponsor: Yunnan Cancer Hospital
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Journal: Efficacy and safety of hetrombopag in the treatment of recombinant human thrombopoietin-resistant thrombocytopenia after allogeneic hematopoietic stem cell transplantation. (Pubmed Central) - Dec 4, 2024
At the last follow-up, 71% of responders had discontinued hetrombopag and sustained their best response. Our results suggested that hetrombopag is an effective treatment option to promote platelet recovery in patients with posttransplant thrombocytopenia, even in patients resistant to rhTPO.
- |||| HRS-5965 / Jiangsu Hengrui Pharma
New P3 trial: Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment (clinicaltrials.gov) - Dec 4, 2024
P3, N=35, Not yet recruiting, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Trial primary completion date: Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer (clinicaltrials.gov) - Dec 4, 2024
P1/2, N=50, Recruiting, Sponsor: Xing Xie
Our results suggested that hetrombopag is an effective treatment option to promote platelet recovery in patients with posttransplant thrombocytopenia, even in patients resistant to rhTPO. Trial primary completion date: Jan 2024 --> Dec 2024
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal, Metastases: Long-term survival in metastatic gastric cancer patient with Apatinib plus S-1 maintenance treatment following first-line chemotherapy-case report. (Pubmed Central) - Dec 3, 2024
After Oxaliplatin combined with S-1 regimen, the effect was up to PR...The combined application of S-1 and Apatinib in gastric cancer maintenance therapy deserves further study. Maintenance therapy for gastric cancer has attracted wide attention, and more large-scale clinical research is under way.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Journal: Trastuzumab-functionalized SK-BR-3 cell membrane-wrapped mesoporous silica nanoparticles loaded with pyrotinib for the targeted therapy of HER-2-positive breast cancer. (Pubmed Central) - Dec 3, 2024
The results of in vivo animal experiments also showed that Tra-CM-MSN-PYR significantly inhibited tumor growth. These results indicate that Tra-CM-MSN-PYR has potential application as a targeted therapy for HER2-positive breast cancer in the future.
- || SHR-1819 / Jiangsu Hengrui Pharma
New P1/2 trial: SHR-1819-204: A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis (clinicaltrials.gov) - Dec 3, 2024
P1/2, N=36, Not yet recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
- ||| HRS9950 / Jiangsu Hengrui Pharma
Trial completion, Trial primary completion date: A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs) (clinicaltrials.gov) - Dec 3, 2024
P2, N=54, Completed, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
These results indicate that Tra-CM-MSN-PYR has potential application as a targeted therapy for HER2-positive breast cancer in the future. Active, not recruiting --> Completed | Trial primary completion date: Jul 2024 --> Nov 2024
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion, Trial completion date, Trial primary completion date, IO biomarker: Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 2, 2024
P2, N=31, Completed, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Active, not recruiting --> Completed | Trial primary completion date: Jul 2024 --> Nov 2024 Trial completion date: Feb 2024 --> Oct 2024 | Trial primary completion date: Feb 2022 --> Mar 2024 | Recruiting --> Completed
- | Hetronifly (serplulimab) / Fosun Pharma, Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Adebrelimab versus serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis in China. (Pubmed Central) - Dec 2, 2024
Trial completion date: Feb 2024 --> Oct 2024 | Trial primary completion date: Feb 2022 --> Mar 2024 | Recruiting --> Completed No abstract available
- | Ibrance (palbociclib) / Pfizer, AiRuiKa (camrelizumab) / Elevar Therapeutics
Trial initiation date: Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas (clinicaltrials.gov) - Dec 2, 2024
P1, N=6, Recruiting, Sponsor: West China Hospital
No abstract available Initiation date: Oct 2023 --> Dec 2024
- | Lonsurf (trifluridine/tipiracil) / Otsuka, Avastin (bevacizumab) / Roche, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer (clinicaltrials.gov) - Dec 2, 2024
P2, N=31, Recruiting, Sponsor: LIN YANG
- || trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P1 trial: SHR-A1811-105: Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer (clinicaltrials.gov) - Dec 2, 2024
P1, N=32, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
Trial completion: Assessment of Gastric Emptying by SHR20004 in Healthy Subjects (clinicaltrials.gov) - Dec 2, 2024
P1, N=28, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Initiation date: Oct 2023 --> Dec 2024 Active, not recruiting --> Completed